PDLIM1

Across TCGA pan-cancer cohorts, PDLIM1 mass-spec protein is linked to patient survival in 6 of 34 cancer types, making it a survival-associated PDLIM1 data layer compared with 25 for mass-spec protein and 3 for mutation status.

The strongest signal is observed in pancreatic ductal adenocarcinoma (PDAC), where higher PDLIM1 mass-spec protein is associated with better disease-free survival. In most high-consensus cancer types, elevated PDLIM1 expression acts as an unfavorable survival marker, although some lineages such as PDAC and GBM show a favorable association.

PDAC, GBM, and LUAD are the cancer types where PDLIM1 mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
PDAC	DFS	Tertile	All	0.865	0.639	<.001	61	view →
GBM	DFS	Quartile	All	0.662	0.210	<.001	14	view →
LUAD	DFS	Tertile	II,III,IV	0.639	0.992	.003	9	view →
OV	DFS	Median	All	0.859	1.000	.032	8	view →
HNSC	DFS	Tertile	III,IV	1.000	0.872	.010	5	view →
CCRCC	OS	Quartile	III,IV	0.886	0.488	.021	2	view →

Pink = unfavorable, green = favorable. Showing the 6 strongest of 6 lineages.

PDLIM1–PDAC (DFS)

Open the PDAC breakdown →